First‐Year IgG Dynamics in IgG4 ‐Related Disease: A Critical Window for Predicting Long‐Term Outcomes
Arthritis & Rheumatology · 2026-07 · 78 (7) · 1500-1511
DOI: 10.1002/art.70056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 23.03.2026. Verfasst von Xin He und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinic…. Hauptthemen laut MEDLINE: Immunoglobulin G, Immunoglobulin G4-Related Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, Beijing Natural Science Foundation, National Key Research and Development Program of China.
Abstract (Originalsprache)
Objective
To investigate longitudinal serum IgG dynamics in IgG4‐related disease (IgG4‐RD) after treatment and assess their prognostic value for relapse.
Methods
A retrospective cohort of 274 newly treated patients with IgG4‐RD was stratified into elevated IgG (n = 186) and normal IgG (n = 88) groups. Treatment responses were evaluated by covariance analysis adjusted for baseline IgG. Longitudinal IgG trends and relapse risk were analyzed using Kaplan–Meier curves and Cox regression.
Results
Elevated baseline IgG level was associated with more severe phenotypes, including male predominance, older age, higher responder index scores, more internal organ involvement, hypocomplementemia, and elevated erythrocyte sedimentation rate/C‐reactive protein level. IgG1 and IgG4 mainly contributed to IgG elevation. After treatment, 79.6% of patients with elevated IgG levels achieved normalization, with the greatest decline in the first year. Glucocorticoid (GC)–based regimens reduced IgG levels more effectively than GC‐sparing therapies and achieved higher normalization rates (85.2% vs 66.7%). Twelve‐month IgG normalization strongly predicted reduced relapse risk. Patients achieving IgG normalization had lower relapse rates (17.9% vs 44.1%; P = 0.001) and superior relapse‐free survival (mean 33.20 [95% CI 32.21–34.19] vs 27.71 [95% CI 24.29–31.13] months; log‐rank P < 0.001). Multivariate Cox regression confirmed failure of 12‐month IgG normalization (hazard ratio [HR] 2.67 [95% CI 1.43–4.99], P = 0.002) and treatment intensity (GCs + weak immunosuppressants [IMs]: HR 0.36, P = 0.012; GCs + potent IMs: HR 0.40, P = 0.020, vs GC‐sparing) as independent relapse determinants.
Conclusion
Baseline IgG elevation marks more severe IgG4‐RD phenotypes. The first treatment year achieving IgG normalization represents a critical prognostic biomarker. Failure to normalize IgG within 12 months markedly increases relapse risk. Longitudinal IgG monitoring supports risk stratification and treatment optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Ke…
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Rheumatology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
ORCID-Profile: Xin He, Yuxue Nie, Jingna Li, Yunyun Fei, Mengtao Li, Wen Zhang
Förderung
- National High Level Hospital Clinical Research Funding
- Beijing Natural Science Foundation
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
He, X., Peng, Y., Nie, Y., Li, J., Sun, B., Zhang, N., Wang, Y., Yang, X., Zhang, J., Zhou, J., Meng, J., Fei, Y., Peng, L., Li, M., & Zhang, W. (2026). First‐Year IgG Dynamics in IgG4 ‐Related Disease: A Critical Window for Predicting Long‐Term Outcomes. Arthritis & Rheumatology, 78(7), 1500-1511. https://doi.org/10.1002/art.70056
Vancouver
He X, Peng Y, Nie Y, Li J, Sun B, Zhang N, et al. First‐Year IgG Dynamics in IgG4 ‐Related Disease: A Critical Window for Predicting Long‐Term Outcomes. Arthritis & Rheumatology. 2026;78(7):1500-1511. doi:10.1002/art.70056
BibTeX
@article{He2026,
author = {He, Xin and Peng, Yu and Nie, Yuxue and Li, Jingna and Sun, Boyuan and Zhang, Nianyi and Wang, Yifei and Yang, Xinli and Zhang, Jialei and Zhou, Jiaxin and Meng, Jie and Fei, Yunyun and Peng, Linyi and Li, Mengtao and Zhang, Wen},
title = {First‐Year IgG Dynamics in IgG4 ‐Related Disease: A Critical Window for Predicting Long‐Term Outcomes},
journal = {Arthritis & Rheumatology},
year = {2026},
volume = {78},
number = {7},
pages = {1500--1511},
doi = {10.1002/art.70056}
}
EUVIMED